References
- Chandramohan V, Mitchell DA, Johnson LA, Sampson JH, Bigner DD. Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncol 2013; 9:977-90; PMID: 23837761; http://dx.doi.org/10.2217/fon.13.47
- Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014; 123:2625-35; PMID: 24578504; http://dx.doi.org/10.1182/blood-2013-11-492231
- Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013; 39:49-60; PMID: 23890063; http://dx.doi.org/10.1016/j.immuni.2013.07.002
- Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther: J Am Soc Gene Ther 2010; 18:843-51; PMID: 20179677; http://dx.doi.org/10.1038/mt.2010.24
- Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD, Sampson JH. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 2009; 19:713-23; PMID: 19744042; http://dx.doi.org/10.1111/j.1750-3639.2009.00318.x
- Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 2012; 23:1043-53; PMID: 22780919; http://dx.doi.org/10.1089/hum.2012.041
- Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, De Leon G, Sayour EJ, McLendon R, Herndon II JE, Healy P, et al. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PloS One 2014; 9:e94281; PMID: 24722266; http://dx.doi.org/10.1371/journal.pone.0094281
- Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, Schmittling RJ, Nair SK, Reap EA, Norberg PK, et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res: Off J Am Assoc Cancer Res 2014; 20:972-84; PMID: 24352643; http://dx.doi.org/10.1158/1078-0432.CCR-13-0709
- Pilon SA, Kelly C, Wei WZ. Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor. J Immunol 2003; 170:1202-8; http://dx.doi.org/10.4049/jimmunol.170.3.1202
- Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID: 23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008